HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Addition of 17-(allylamino)-17-demethoxygeldanamycin to a suboptimal caspofungin treatment regimen in neutropenic rats with invasive pulmonary aspergillosis delays the time to death but does not enhance the overall therapeutic efficacy.

Abstract
Caspofungin (CAS) which is used as salvage therapy in patients with invasive pulmonary aspergillosis (IPA) inhibits the 1,3-β-D-glucan synthesis in Aspergillus fumigatus. Inhibiting 1,3-β-D-glucan synthesis induces a stress response and in an invertebrate model it was demonstrated that inhibiting this response with geldamycin enhanced the therapeutic efficacy of CAS. Since geldamycin itself is toxic to mammalians, the therapeutic efficacy of combining geldamycin with CAS was not studied in rodent models. Therefore in this study we investigated if the geldamycin derivate 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) was able to enhance the therapeutic efficacy of CAS in vitro and in our IPA model in transiently neutropenic rats. In vitro we confirmed the earlier demonstrated synergy between 17-AAG and CAS in ten A. fumigatus isolates. In vivo we treated A. fumigatus infected neutropenic rats with a sub-optimal dose of 0.75 mg/kg/day CAS and 1 mg/kg/day 17-AAG for ten days. Survival was monitored for 21 days after fungal inoculation. It appeared that the addition 17-AAG delayed death but did not improve overall survival of rats with IPA. Increasing the doses of 17-AAG was not possible due to hepatic toxicity. This study underlines the need to develop less toxic and more fungal specific geldamycin derivatives and the need to test such drugs not only in invertebrate models but also in mammalian models.
AuthorsJeannine M Refos, Alieke G Vonk, Marian T Ten Kate, Kimberly Eadie, Henri A Verbrugh, Irma A J M Bakker-Woudenberg, Wendy W J van de Sande
JournalPloS one (PLoS One) Vol. 12 Issue 7 Pg. e0180961 ( 2017) ISSN: 1932-6203 [Electronic] United States
PMID28742113 (Publication Type: Journal Article)
Chemical References
  • Antifungal Agents
  • Benzoquinones
  • Echinocandins
  • Lactams, Macrocyclic
  • Lipopeptides
  • tanespimycin
  • Caspofungin
Topics
  • Animals
  • Antifungal Agents (administration & dosage)
  • Aspergillus fumigatus (drug effects)
  • Benzoquinones (administration & dosage, toxicity)
  • Caspofungin
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • Echinocandins (administration & dosage)
  • Female
  • Humans
  • Invasive Pulmonary Aspergillosis (complications, drug therapy, microbiology)
  • Lactams, Macrocyclic (administration & dosage, toxicity)
  • Lipopeptides (administration & dosage)
  • Microbial Sensitivity Tests
  • Neutropenia (complications)
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: